Watanabe T. Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas. World J Gastroenterol 2023; 29(48): 6179-6197 [PMID: 38186866 DOI: 10.3748/wjg.v29.i48.6179]
Corresponding Author of This Article
Takuya Watanabe, MD, PhD, Director, Doctor, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, 1-2-21 Aoyama, Nishi-ku, Niigata 9502002, Japan. nabetaku@dia-net.ne.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Dec 28, 2023; 29(48): 6179-6197 Published online Dec 28, 2023. doi: 10.3748/wjg.v29.i48.6179
Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas
Takuya Watanabe
Takuya Watanabe, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, Niigata 9502002, Japan
Author contributions: Watanabe T solely contributed to this manuscript.
Conflict-of-interest statement: There is no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Takuya Watanabe, MD, PhD, Director, Doctor, Department of Internal Medicine and Gastroenterology, Watanabe Internal Medicine Aoyama Clinic, 1-2-21 Aoyama, Nishi-ku, Niigata 9502002, Japan. nabetaku@dia-net.ne.jp
Received: September 24, 2023 Peer-review started: September 24, 2023 First decision: October 29, 2023 Revised: November 2, 2023 Accepted: December 18, 2023 Article in press: December 18, 2023 Published online: December 28, 2023
Core Tip
Core Tip: Recently, the incidence of follicular lymphoma (FL) has increased in Asia, Europe, and the United States, with the number of gastrointestinal FL cases expected to increase. This article reviews the recent literature on the molecular origins of, innovative treatments for, and clinical trial findings on FL, focusing on gastrointestinal FL. Genetic factors [e.g., t(14;18) translocation and B-cell lymphoma 2 overexpression] drive FL growth, while microRNAs aid in its diagnosis and prognosis. Although recent trials have reported enhanced treatment outcomes, curative therapies remain elusive, and combinatorial regimens have not been optimized. Hence, gastroenterologists require a more comprehensive understanding of gastrointestinal FL pathogenesis to facilitate improved therapeutic outcomes.
